Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Kestrel Therapeutics, Inc.

Clinical trials sponsored by Kestrel Therapeutics, Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New pill targets Hard-to-Treat KRAS cancers in first human trial Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

New pill targets Hard-to-Treat KRAS cancers in first human trial

Disease control Recruiting now

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

Phase 1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control

Last updated Jul 01, 2026 00:00 UTC